Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Show all 309 references

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Items 301–400 of 1,003

Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art
Páez-Carpio, A., Gómez, F. M., Olivé, G., Paredes, P., Baetens, T. R., Carrero, E., Sánchez, M., & Vollmer, I. (2021) · Insights into Imaging · doi:10.1186/s13244-021-00997-5 · Cited by 57
The Landscape of Actionable Gene Fusions in Colorectal Cancer
Pagani, F., Randon, G., Guarini, V., Raimondi, A., Prisciandaro, M., Lobefaro, R., Bartolomeo, M. D., Sozzi, G., de Braud, F., Gasparini, P., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215319 · Cited by 58
Precision medicine for metastatic colorectal cancer in clinical practice
Riedesser, J. E., Ebert, M. P. A., & Betge, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211072703 · Cited by 58
Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients
Adam, R. A., Yi, B., Innominato, P. F., Barroso, E., Laurent, C., Giuliante, F., Capussotti, L., Lapointe, R. W., Regimbeau, J., López‐Ben, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.009 · Cited by 58
Self-citation
Magnolin promotes autophagy and cell cycle arrest via blocking LIF/Stat3/Mcl-1 axis in human colorectal cancers
Yu, H., Yin, S., Zhou, S., Shao, Y., Sun, J., Pang, X., Han, L., Zhang, Y., Gao, X., Jin, C., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0660-4 · Cited by 56
Curcumin: A therapeutic strategy for colorectal cancer?
de Porras, V. R., Layos, L., & Martinez‐Balibrea, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.004 · Cited by 58
Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
Zoetemelk, M., Ramzy, G. M., Rausch, M., & Nowak-Sliwinska, P. M. (2020) · Molecules · doi:10.3390/molecules25112614 · Cited by 57
Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma
Barbier, C. E., Heindryckx, F., & Lennernäs, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313051 · Cited by 53
Targeted Therapy of Colorectal Cancer
Seeber, A., & Gastl, G. A. (2016) · Oncology Research and Treatment · doi:10.1159/000453027 · Cited by 54
Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases
Granata, V., Fusco, R., Catalano, O., Avallone, A., Palaia, R., Botti, G., Tatangelo, F., Granata, F. M., Cascella, M., Izzo, F., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179951 · Cited by 54
Targeted therapy for metastatic colorectal cancer
Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., Segelov, E., Roy, A. C., Tebbutt, N. C., Pavlakis, N., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1502664 · Cited by 54
Self-citation
Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis
Ottaiano, A., Normanno, N., Facchini, S., Cassata, A., Nappi, A. G., Romano, C., Silvestro, L., Stefano, A. D., Rachiglio, A. M., Roma, C., et al. (2020) · Cancers · doi:10.3390/cancers12071919 · Cited by 53
Self-citation
Complement System: An Immunotherapy Target in Colorectal Cancer
Talaat, I. M., Elemam, N. M., & Saber-Ayad, M. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810993 · Cited by 54
The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases
Gorgen, A., Muaddi, H., Zhang, W., McGilvray, I. D., Gallinger, S., & Sapisochín, G. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9531925 · Cited by 53
Recent advances in treatment for colorectal liver metastasis
Oki, E., Ando, K., Nakanishi, R., Sugiyama, M., Nakashima, Y., Kubo, N., Kudou, K., Saeki, H., Nozoe, T., Emi, Y., et al. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12071 · Cited by 54
Precision treatment in colorectal cancer: Now and the future
Yau, T. O. (2019) · JGH Open · doi:10.1002/jgh3.12153 · Cited by 54
Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score
Gasser, E., Braunwarth, E., Riedmann, M., Cardini, B., Fadinger, N., Presl, J., Klieser, E., Ellmerer, P., Dupré, A., Imai, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217411 · Cited by 53
Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX
Escalante, P. I., Quiñones, L. A., & Contreras, H. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010075 · Cited by 54
Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach
Valenzuela, G., Canepa, J., Simonetti, C., de Zaldívar, L. S., Marcelain, K., & González‐Montero, J. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i11.1000 · Cited by 52
Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer
He, X., Jiang, Y. J., Zhang, L., Li, Y., Hu, X., Hua, G., Cai, S., Mo, S., & Peng, J. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1190637 · Cited by 56
The Importance of Optimal Thermal Ablation Margins in Colorectal Liver Metastases: A Systematic Review and Meta-Analysis of 21 Studies
Chlorogiannis, D., Sotirchos, V. S., Georgiades, C. S., Filippiadis, D. K., Arellano, R. S., Gönen, M., Makris, G. C., Garg, T., & Sofocleous, C. T. (2023) · Cancers · doi:10.3390/cancers15245806 · Cited by 52
Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis
Lin, J., Peng, J., Zhao, Y., Luo, B., Zhao, Y., Deng, Y., Sui, Q., Gao, Y., Zeng, Z., Lu, Z., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2538-8 · Cited by 52
Symptoms during chemotherapy in colorectal cancer patients
Röhrl, K., Guren, M. G., Småstuen, M. C., & Rustøen, T. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-018-4598-y · Cited by 52
Squamous cell anal cancer: Management and therapeutic options
Pessia, B., Romano, L., Giuliani, A., Lazzarin, G., Carlei, F., & Schietroma, M. (2020) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2020.04.016 · Cited by 52
Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
Klein‐Scory, S., Wahner, I., Maslova, M., Al‐Sewaidi, Y., Pohl, M., Mika, T., Ladigan, S., Schroers, R., & Baraniskin, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01115 · Cited by 52
T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer
Fathi, M., Pustokhina, I., Kuznetsov, S. V., Khayrullin, M., Hojjat‐Farsangi, M., Karpisheh, V., Jalili, A., & Jadidi‐Niaragh, F. (2021) · IUBMB Life · doi:10.1002/iub.2461 · Cited by 53
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 56
The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)
van de Vlasakker, V. C. J., Lurvink, R. J., Cashin, P., Ceelen, W. P., D, M. D. M., Goèré, D., González‐Moreno, S., Lehmann, K., Li, Y., Moran, B., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.05.023 · Cited by 51
A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway
Wu, X., Xu, L., Li, X., Zhou, Y., Han, X., Zhang, W., Wang, W., Guo, W., Liu, W., Xu, Q., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06073-8 · Cited by 53
Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
Raimondi, C., Nicolazzo, C., Belardinilli, F., Loreni, F., Gradilone, A., Mahdavian, Y., Gelibter, A. J., Giannini, G., Cortesi, E., & Gazzaniga, P. (2019) · Cancers · doi:10.3390/cancers11010042 · Cited by 51
Standardized Pathology Report for Colorectal Cancer, 2nd Edition
Kim, B., Kim, J. M., Kang, G. H., Chang, H. J., Kang, D. W., Kim, J. H., Bae, J. M., Seo, A. N., Park, H. S., Kang, Y. K., et al. (2019) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2019.09.28 · Cited by 56
Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021
Yamamoto, M., Yoshida, M., Furuse, J., Sano, K., Ohtsuka, M., Yamashita, S., Beppu, T., Iwashita, Y., Wada, K., Nakajima, T. E., et al. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.868 · Cited by 51
Self-citation
Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: surgeon’s perspective
Franko, J. (2018) · Pleura and Peritoneum · doi:10.1515/pp-2018-0102 · Cited by 50
Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer
Alvarez, J. A., Shi, Q., Dasari, A. N., García‐Aguilar, J., Sanoff, H. K., George, T. J., Hong, T. S., Yothers, G., Philip, P., Nelson, G. D., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12529-7 · Cited by 50
Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer
Yang, Y., Wang, G., Zhu, D., Huang, Y., Luo, Y., Su, P., Chen, X., & Wang, Q. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4044 · Cited by 50
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
Goldberg, R. M., Montagut, C. O., Wainberg, Z. A., Ronga, P., Audhuy, F., Taı̈eb, J., Stintzing, S., Siena, S., & Santini, D. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000353 · Cited by 51
Self-citation
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa, L., Bozzarelli, S., Pietrantonio, F., Cordio, S., Lonardi, S., Toppo, L., Zaniboni, A., Bordonaro, R., Di Bartolomeo, M., Tomasello, G., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.004 · Cited by 50
Disappearing liver metastases: A systematic review of the current evidence
Tsilimigras, D. I., Ntanasis‐Stathopoulos, I., Paredes, A. Z., Moris, D., Gavriatopoulou, M., Cloyd, J. M., & Pawlik, T. M. (2019) · Surgical Oncology · doi:10.1016/j.suronc.2019.02.005 · Cited by 50
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients
Re, M. D., Cinieri, S., Michelucci, A., Salvadori, S., Loupakis, F., Schirripa, M., Cremolini, C., Crucitta, S., Barbara, C., Leo, A. D., et al. (2019) · The Pharmacogenomics Journal · doi:10.1038/s41397-019-0077-1 · Cited by 50
Self-citation
Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS)
Baratti, D., D, S. K. M., Azmi, N., Guagliò, M., Montenovo, M., & D, M. D. M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07935-2 · Cited by 50
Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer
Martin, S. Z., Wagner, D., Hörner, N., Horst, D. A., Lang, H., Tagscherer, K. E., & Roth, W. (2019) · BMC Cancer · doi:10.1186/s12885-019-6270-4 · Cited by 54
Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells
Rodrigues, J. G., Duarte, H. O., Gomes, C., Balmaña, M., Martins, Á. M., Hensbergen, P. J., de Ru, A. H., Lima, J. P., Albergaria, A., van Veelen, P. A., et al. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00606-z · Cited by 47
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T. W., Kiani, A., Vehling‐Kaiser, U., Al‐Batran, S., Heintges, T., Kahl, C., Seipelt, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22396 · Cited by 50
Self-citation
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer
Tabernero, J. M., Grothey, A. F., Arnold, D., de Gramont, A., Ducreux, M. P., O'Dwyer, P. J., Tahiri, A., Gilberg, F., Irahara, N., Schmoll, H., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100559 · Cited by 49
Self-citation
A bioinformatics approach to identify a disulfidptosis-related gene signature for prognostic implication in colon adenocarcinoma
Hu, G., Yao, H., Wei, Z., Li, L., Yu, Z., Li, J., Luo, X., & Guo, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-39563-y · Cited by 49
Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial
Glockzin, G., Zeman, F., Croner, R. S., Königsrainer, A., Pelz, J. O. W., Ströhlein, M. A., Rau, B., Arnold, D., Koller, M. T., Schlitt, H. J., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.011 · Cited by 50
Self-citation
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial
Anandappa, G., Lampis, A., Cunningham, D., Khan, K. H., Kouvelakis, K., Vlachogiannis, G., Hedayat, S., Tunariu, N., Rao, S., Watkins, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3769 · Cited by 49
Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial
Garlipp, B., Gibbs, P., Hazel, G. A. V., Jeyarajah, R., Martin, R. C. G., Bruns, C. J., Lang, H., Manas, D., Ettorre, G. M., Pardo, F., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11283 · Cited by 48
Self-citation
Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis
Kawai, S., Takeshima, N., Hayasaka, Y., Notsu, A., Yamazaki, M., Kawabata, T., Yamazaki, K., Mori, K. P., & Yasui, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-07823-7 · Cited by 49
Stereotactic and Robotic Minimally Invasive Thermal Ablation of Malignant Liver Tumors: A Systematic Review and Meta-Analysis
Tinguely, P., Paolucci, I., Ruiter, S. J. S., Weber, S., de Jong, K. D., Candinas, D., Freedman, J., & Engstrand, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2021.713685 · Cited by 49
The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review
Boeckx, N., Janssens, K., Camp, G. V., Rasschaert, M. A., Papadimitriou, K., Peeters, M., & de Beeck, K. O. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.003 · Cited by 48
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
Laurent‐Puig, P., Grisoni, M.-L., Heinemann, V., Liebaert, F., Neureiter, D., Jung, A., Montestruc, F., Gaston‐Mathé, Y., Thiébaut, R., & Stintzing, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1324 · Cited by 48
Self-citation
Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting
Yamaguchi, K., Komatsu, Y., Satoh, T., Uetake, H., Yoshino, T., Nishida, T., Yamazaki, N., Takikawa, H., Morimoto, T., Chosa, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0377 · Cited by 48
Self-citation
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes
Ragulan, C., Eason, K., Fontana, E., Nyamundanda, G., Tarazona, N., Patil, Y., Poudel, P., Lawlor, R. T., Rio, M. D., Koo, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43492-0 · Cited by 45
Self-citation
Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm
Jeyarajah, D. R., Doyle, M. B. M., Espat, N. J., Hansen, P., Iannitti, D. A., Kim, J., Thambi-Pillai, T. C., & Visser, B. C. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2020.01.09 · Cited by 47
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R., & André, T. (2020) · Cancers · doi:10.3390/cancers12092350 · Cited by 49
Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
Yu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Management of Metastatic Colorectal Cancer: SUNLIGHT Study Design
Tabernero, J. M., Taı̈eb, J., Prager, G. W., Ciardiello, F., Fakih, M., Leger, C., Fougeray, R., Amellal, N., & Cutsem, E. V. (2021) · Future Oncology · doi:10.2217/fon-2020-1238 · Cited by 50
Self-citation
Amelioration of oxidative stress, inflammation and tumor promotion by Tin oxide-Sodium alginate-Polyethylene glycol-Allyl isothiocyanate nanocomposites on the 1,2-Dimethylhydrazine induced colon carcinogenesis in rats
Wei, W., Li, R., Liu, Q., Seshadri, V. D., Veeraraghavan, V. P., Surapaneni, K. M., & Rengarajan, T. (2021) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2021.103238 · Cited by 49
Anti‐angiogenesis in colorectal cancer therapy
Yang, Z., Zhang, X., Bai, X., Xi, X., Liu, W., & Zhong, W. (2024) · Cancer Science · doi:10.1111/cas.16063 · Cited by 50
Comparison of Western and Asian Guidelines Concerning the Management of Colon Cancer
Pellino, G., Warren, O. J., Mills, S. C., Rasheed, S., Tekkis, P. P., & Kontovounisios, C. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001012 · Cited by 47
Trifluridine/Tipiracil: An Emerging Strategy for the Management of Gastrointestinal Cancers
Peeters, M., Cervantes, A. M. R., Vera, S. R. M., & Taı̈eb, J. (2018) · Future Oncology · doi:10.2217/fon-2018-0147 · Cited by 48
Self-citation
SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand
Palmirotta, R., Carella, C., Silvestris, E., Cives, M., Stucci, S. L., Tucci, M., Lovero, D., & Silvestris, F. (2018) · Oncotarget · doi:10.18632/oncotarget.25256 · Cited by 47
Probing the colorectal cancer proteome for biomarkers: Current status and perspectives
Lee, P. Y., Chin, S., Low, T. Y., & Jamal, R. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.06.014 · Cited by 46
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer
Giordano, G., Parcesepe, P., D'Andrea, M. R., Coppola, L., Raimo, T. D., Remo, A., Manfrin, E., Fiorini, C., Scarpa, A., Amoreo, C. A., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1019-5 · Cited by 47
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
Cardone, C., Blauensteiner, B., Moreno‐Viedma, V., Martini, G., Simeon, V., Vitiello, P. P., Ciardiello, D., Belli, V., Matrone, N., Troiani, T., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.07.010 · Cited by 47
Self-citation
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer
Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102172 · Cited by 47
Self-citation
Nanotechnology-based siRNA delivery strategies for metastatic colorectal cancer therapy
Sousa, A. R., Oliveira, A. V., Oliveira, M. J., & Sarmento, B. F. C. C. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118530 · Cited by 46
Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
Jin, K., Chen, B., Liu, Y., Lan, H., & Yan, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01763-9 · Cited by 48
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
Ghazi, B., Ghanmi, A. E., Kandoussi, S., Ghouzlani, A., & Badou, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978195 · Cited by 47
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
Taïeb, J., Sinicrope, F. A., Pederson, L., Lonardi, S., Alberts, S. R., George, T. J., Yothers, G., Cutsem, E. V., Saltz, L. B., Ogino, S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.006 · Cited by 52
Self-citation
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
Viganò, L., Darwish, S. S., Rimassa, L., Cimino, M., Carnaghi, C., Donadon, M., Procopio, F., Personeni, N., Fabbro, D. D., Santoro, A., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6387-8 · Cited by 46
Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?
Pan, Z., Peng, J., Lin, J., Chen, G., Wu, X., Lu, Z., Deng, Y., Zhao, Y., Sui, Q., & Wan, D. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0298-8 · Cited by 46
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology
Corti, G., Bartolini, A., Crisafulli, G., Novara, L., Rospo, G., Montone, M., Negrino, C., Mussolin, B., Buscarino, M., Isella, C., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.008 · Cited by 45
Self-citation
Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers
Zhao, Y., Li, J., Li, D., Wang, Z., Zhao, J., Wu, X., Sun, Q., Lin, P. P., Plum, P. S., Damanakis, A. I., et al. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.026 · Cited by 47
Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
Hamers, P. A. H., Elferink, M. A. G., Stellato, R. K., Punt, C. J. A., May, A. M., Koopman, M., & Vink, G. R. (2020) · International Journal of Cancer · doi:10.1002/ijc.33200 · Cited by 50
Self-citation
Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases
Rizzetto, F., Calderoni, F., Mattia, C. D., Defeudis, A., Giannini, V., Mazzetti, S., Vassallo, L., Ghezzi, S., Bianchi, A. S., Marsoni, S., et al. (2020) · European Radiology Experimental · doi:10.1186/s41747-020-00189-8 · Cited by 46
Centralized repeated resectability assessment of patients with colorectal liver metastases during first-line treatment: prospective study
Isoniemi, H., Uutela, A., Nordin, A. J., Lantto, E., Kellokumpu, I., Ovissi, A., Kosunen, J., Kallio, R., Soveri, L., Salminen, T., et al. (2021) · British journal of surgery · doi:10.1093/bjs/znaa145 · Cited by 47
Insulin-Like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) Is a Prognostic Biomarker and Associated with Chemotherapy Responsiveness in Colorectal Cancer
Chen, H.-M., Lin, C., Chen, W., Jiang, J., Yang, S.-H., Chang, S., Ho, C., Yang, C., Huang, S., Chao, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136940 · Cited by 46
Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases
Bolhuis, K., Erve, I. V. ’., Mijnals, C., Diemen, P. M. D., Huiskens, J., Komurcu, A., López‐Yurda, M., van den Broek, D. A., Swijnenburg, R., Meijer, G. A., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103498 · Cited by 46
Self-citation
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study
Cao, Y., Zhang, G., Zhang, J., Yang, Y., Ren, J., Bao, H., Yan, X., Wang, Z., Zhao, Z., Han, T., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2021.687771 · Cited by 45
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance
Dong, D., Xue, Y., Xu, J., Yu, N. H., Liu, Z., & Sun, Y. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101125 · Cited by 49
Multidisciplinary approach of colorectal cancer liver metastases
Fiorentini, G., Sarti, D., Aliberti, C., Carandina, R., Mambrini, A., & Guadagni, S. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i3.190 · Cited by 46
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study
Oki, E., Kato, T., Bando, H., Yoshino, T., Muro, K., Taniguchi, H., Kagawa, Y., Yamazaki, K., Yamaguchi, T., Tsuji, A., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.01.011 · Cited by 45
Self-citation
Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers
Wu, Z., Guo, H.-F., Xu, H., & Cheung, N. V. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0026 · Cited by 48
SMAD 4 alteration associates with invasive‐front pathological markers and poor prognosis in colorectal cancer
Oyanagi, H., Shimada, Y., Nagahashi, M., Ichikawa, H., Tajima, Y., Abe, K., Nakano, M., Kameyama, H., Takii, Y., Kawasaki, T., et al. (2019) · Histopathology · doi:10.1111/his.13805 · Cited by 45
Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response
Jia, N., Sun, Z., Gao, X. Y., Cheng, Y., Zhou, Y., Shen, C., Chen, W., Wang, X., Shi, R., Li, N., et al. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00470 · Cited by 45
Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
Vivancos, A. P., Aranda, E., Benavides, M., Élez, E., Gómez‐España, M. A., Toledano‐Fonseca, M., Álvarez, M., Chica-Parrado, M. D. R., García‐Barberán, V., & Díaz‐Rubio, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-45616-y · Cited by 47
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
Bachet, J., Wyrwicz, L. S., Price, T. J., Cremolini, C., Phelip, J., Portales, F., Özet, A., Çiçin, İ., Atlan, D., Becquart, M., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000698 · Cited by 45
Self-citation
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
Yoshida, Y., Yamada, T., Kamiyama, H., Kosugi, C., Ishibashi, K., Yoshida, H., Ishida, H., Yamaguchi, S., Kuramochi, H., Fukazawa, A., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01794-8 · Cited by 46
Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases
Kobayashi, S., Nakamura, Y., Taniguchi, H., Odegaard, J. I., Nomura, S., Kojima, M., Sugimoto, M., Konishi, M., Gotohda, N., Takahashi, S., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09449-8 · Cited by 45
Self-citation
Harnessing Ferroptosis to Overcome Drug Resistance in Colorectal Cancer: Promising Therapeutic Approaches
Cheng, X., Zhao, F., Ke, B., Chen, D., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15215209 · Cited by 44
Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine
Paulík, A., Nekvindová, J., & Filip, S. (2018) · Tumori Journal · doi:10.1177/0300891618811283 · Cited by 44
Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?
Raphael, M. J., & Karanicolas, P. J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02505 · Cited by 44
Prediction of Clinical Precision Chemotherapy by Patient‐Derived 3D Bioprinting Models of Colorectal Cancer and Its Liver Metastases
Sun, H., Sun, L., Ke, X., Liu, L., Li, C., Jin, B., Wang, P., Jiang, Z., Zhao, H., Yang, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202304460 · Cited by 47
Novel Systemic Therapies for Advanced Gastric Cancer
Kim, H. J., & Oh, S. C. (2018) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2018.18.e3 · Cited by 45
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Stein, A., Moehler, M. H., Trojan, J., Goekkurt, E., & Vogel, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.001 · Cited by 44
Comparison of guidelines for the management of rectal cancer
Luzietti, E., Pellino, G., Nikolaou, S., Qiu, S., Mills, S., Warren, O. J., Tekkis, P. P., & Kontovounisios, C. (2018) · BJS Open · doi:10.1002/bjs5.88 · Cited by 44
TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial
Chauhan, N., Mulcahy, M. F., Salem, R., Benson, A. B., Boucher, É., Bukovcan, J., Cosgrove, D., Laframboise, C., Lewandowski, R. J., Master, F., et al. (2019) · JMIR Research Protocols · doi:10.2196/11545 · Cited by 44
Self-citation

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks